Clinical trials: Cannabidiol
Autism, Autism Spectrum Disorder
Placebo-Controlled Study of Terpenes-Enriched Cannabis Oil T1/C28 for Children With Autism
The goal of this clinical trial is to determine whether cannabidiol (CBD, 28%) combined with terpenes and a small amount of THC (1%) can help reduce symptoms of autism, and to evaluate the safety of this treatment.
- Trial name
- TECA (NCT07199218)
- Testing
- Terpenes-Enriched CBD-Predominant Oil, Terpenes-Enriched CBD Oil (THC-Free)
- Where
- Israel
- Volunteers
- 78 people
- Sponsor
- Bazelet Nehushtan LtD.
Opioid Use Disorder
Cannabidiol in the Treatment of Opioid Use Disorder
The long-term goal of the project is to determine whether cannabidiol (CBD) can reduce craving and relapse in individuals with opioid use disorder (OUD).
- Trial name
- NCT06206291
- Testing
- Cannabidiol (CBD) 200mg, Cannabidiol (CBD) 400mg
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- Yasmin Hurd
Steroid Dependent Crohn's Disease
A Phase 2a Study to Evaluate the Safety, Tolerability and Efficacy of Cannabidiol as a Steroid-sparing Therapy in Steroid-dependent Crohn's Disease Patients
Treatment will start with dose escalation in addition to Standard of Care (steroid therapy with or without additional therapies) .
- Trial name
- NCT04056442
- Testing
- Cannabidiol , synthetic form
- Where
- 3 sites in Israel
- Volunteers
- 15 people
- Sponsor
- Stero Biotechs Ltd.
Opioid-use Disorder
Cannabidiol Use to Reduce Cravings in Individuals With Opioid Use Disorder on Buprenorphine
The purpose of this week-long study is to determine the impact of cannabidiol on cue-induced cravings among individuals with opioid use disorder who are stable on sublingual buprenorphine treatment.
- Trial name
- CURB (NCT04192370)
- Testing
- Cannabidiol 600mg
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Brigham and Women's Hospital
Diet Modification
Cannabinoid Supplementation on Vascular and Cognitive Function
Cannabidiol (CBD) is a bioactive cannabinoid compound in marijuana (cannabis sativa), but unlike Δ9 tetrahydrocannabinol (THC), lacks the psychoactivity effect of THC.
- Trial name
- NCT03295903
- Testing
- Cannabidiol supplement
- Where
- Canada
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
Post Traumatic Stress Disorder, Traumatic Brain Injury
Cannabidiol as a Treatment for PTSD and PTSD Comorbid With TBI
This will be a randomized placebo controlled study to test the efficacy of cannabidiol (CBD) as a treatment for symptoms of post-traumatic stress disorder (PTSD).
- Trial name
- NCT04550377
- Testing
- Cannabidiol
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- NYU Langone Health
Menstrual Discomfort
The Effects of CBD Isolate on Menstrual-Related Symptoms
The goal of this open-label clinical trial is to compared two different doses for treating menstrual-related symptoms in individuals who experience regular menstrual cycles (occurring for 4-8 days every 21-28 days).
- Trial name
- NCT05679830
- Testing
- Cannabidiol
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Canopy Growth Corporation
Tuberous Sclerosis Complex Associated Neuropsychiatric Disease
A Study to Investigate Behavioral and Other Co-Occurring Outcomes With Epidiolex as Add-On Therapy in Participants Aged 1 to 65 Years of Age With Tuberous Sclerosis Complex
The purpose of this study is to investigate behavioral and other co-occurring outcomes with EPID(I/Y)OLEX as an add-on therapy in participants aged 1 to 65 years with tuberous sclerosis complex (TSC) who experience seizures.
- Trial name
- EpiCom (NCT05864846)
- Testing
- Cannabidiol Oral Solution [Epidiolex]
- Where
- 19 sites in United States, Canada and 2 more
- Volunteers
- 79 people
- Sponsor
- Jazz Pharmaceuticals
Alzheimer Disease
Use of a Cannabinoids as a Treatment Strategy for Alzheimer's Disease
Brief Summary: The objective of the study is to evaluate the effect of cannabinoids on Alzheimer's Disease. This is a double-blind, randomized, placebo-controlled clinical trial.
- Trial name
- DAZACANN (NCT06570928)
- Testing
- Cannabis
- Where
- Brazil
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Federal University of Latin American Integration
Comparative Bioavailability
Cannabidiol Bioavailability Trial With Oral Multiple Dose Administration
Glatt Pharmaceutical Services GmbH \& Co. KG is developing a new CBD granules formulation (GLA-015 / Cannabidiol 1500 mg 29,7% w/w GRA BLD P) which is intended to be used in the treatment of the new Coronavirus disease 2019…
- Trial name
- NCT04790136
- Testing
- GLA-015, DAC C-052 "Cannabidiol" / NRF 22.10 "Oily cannabidiol solution 100 mg/ml"
- Where
- Germany
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- SocraTec R&D GmbH
Focal Seizures
A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures
Cannabidiol oral solution (CBD-OS) is approved in the US for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or Tuberous sclerosis complex (TSC) in patients 1 year of age and older.
- Trial name
- NCT07233239
- Testing
- CBD-OS
- Where
- 24 sites in United States
- Volunteers
- 100 people
- Sponsor
- Jazz Pharmaceuticals
Obsessive-Compulsive Disorder, Trichotillomania (Hair-Pulling Disorder)
Epidiolex in Obsessive Compulsive Disorder and Related Disorders
The primary objective of the proposed study is to evaluate the safety and efficacy of Epidiolex (cannabidiol) in adults with obsessive compulsive and related disorders (OCRDs).
- Conditions
- Obsessive-Compulsive Disorder, Trichotillomania (Hair-Pulling Disorder), Tourette Syndrome, Hoarding Disorder
- Trial name
- NCT04978428
- Testing
- Cannabidiol
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Chicago
Post-operative Pain
CBD Knee Scope Study
This is a prospective, randomized, nonblinded trial to evaluate the effectiveness of Cannabidiol (CBD) oil on post-operative pain control compared to opioid medications after a knee arthroscopy.
- Trial name
- CBDS (NCT05934500)
- Testing
- Cannabidiol Oil
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Foundation for Orthopaedic Research and Education
Bipolar Disorder
Assessing the Impact of Cannabidiol for Anxiety and Depression in Bipolar Disorder
Preliminary data have suggested that cannabidiol (CBD) may have a number of clinical benefits, including anti-anxiety and antidepressant properties.
- Trial name
- NCT05457465
- Testing
- Cannabidiol
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Mclean Hospital
Generalized Anxiety Disorder, Social Anxiety Disorder
Cannabinoids for the Treatment of Anxiety Disorders: An 8-Week Pilot Study
This proposed study aims to evaluate the efficacy of a daily oral cannabinoid oil preparation in treating symptoms of DSM-5 anxiety disorders, using a two-arm, 8-week randomized, placebo-controlled trial in adults aged 21-65…
- Conditions
- Generalized Anxiety Disorder, Social Anxiety Disorder, Panic Disorder, Agoraphobia
- Trial name
- NCT04569760
- Testing
- 50:2 mg(CBD:THC)/ml - Cannabinoid Oil Oral Preparation- titrated as tolerated up to a maximum 8mls twice daily (200 mg- 800 mg total dose)
- Where
- Canada
- Sponsor
- McMaster University
Cannabis, THC
Modulation of THC Effects by CBD: a Dose-ranging Study
The purposes of this study are 1) to determine if CBD modulates THC-induced acute psychoactive effects at different CBD:THC ratios, compared with the control product (0:20, 20:20, 40:20, 80:20, 120:20) and 2) to determine if…
- Trial name
- SPECTRE (NCT06099379)
- Testing
- ∆9-tetrahydrocannabinol
- Where
- Canada
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Chemotherapy-induced Peripheral Neuropathy
Cannabidiol for Prevention of Chemotherapy-induced Peripheral Neuropathy
This protocol describes a phase II trial investigating the efficacy of CBD in paclitaxel- and oxaliplatin-induced peripheral neuropathy.
- Trial name
- CINCAN-2 (NCT04582591)
- Testing
- Cannabidiol 100 MG/ML
- Where
- Denmark
- Volunteers
- 54 people
- Sponsor
- Zealand University Hospital
Epilepsy
A Study of Possible Drug-drug Interactions Between Stiripentol or Valproate and Cannabidiol in Patients With Epilepsy
This trial consists of 2 parts: a double-blinded phase and an open-label extension phase. The blinded phase only will be described in this record.
- Trial name
- NCT02607891
- Testing
- GWP42003-P
- Where
- 5 sites in Netherlands, Spain and 1 more
- Volunteers
- 35 people
- Sponsor
- Jazz Pharmaceuticals
Breast Cancer Female
Investigating the Potential Role of a Novel Quadrate Combination Therapy Mifepristone(Antiprogestrone), Tamoxifen, Retinoic Acid and Cannabidiol ( Selective Cyp 26 Inhibitor) for Treating Early Breast Cancer.
Investigating the potential role of a novel quadrate combination therapy Mifepristone(Antiprogestrone), Tamoxifen, Retinoic acid and Cannabidiol ( selective cyp 26 inhibitor) for treating early breast cancer.
- Trial name
- NCT05016349
- Testing
- All trans-retinoic acid, 13-Cis Retinoic Acid plus Tocopherol, Mifepristone
- Volunteers
- 160 people
- Sponsor
- Mahmoud Ramadan mohamed Elkazzaz
Breast Cancer
CBD for Breast Cancer Primary Tumors
This is a randomized placebo controlled partially blinded window of opportunity trial. A maximum of 84 patients with invasive breast cancer will be enrolled.
- Trial name
- NCT06148038
- Testing
- CBD Oral, Control
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- Medical University of South Carolina